Live-Attenuated Respiratory Syncytial Virus Vaccines

  • Ruth A. Karron
  • Ursula J. Buchholz
  • Peter L. Collins
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 372)


Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.


  1. Ambrose CS, Wu X, Belshe RB (2010) The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 29:806–811PubMedCrossRefGoogle Scholar
  2. Ambrose CS, Levin MJ, Belshe RB (2011) The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Respir Viruses 5:67–75CrossRefGoogle Scholar
  3. Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH (2005) Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23:4631–4646 Google Scholar
  4. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685–696PubMedCrossRefGoogle Scholar
  5. Bermingham A, Collins PL (1999) The M2–2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A 96:11259–11264PubMedCentralPubMedCrossRefGoogle Scholar
  6. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F (2012) Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 31:109–114PubMedCrossRefGoogle Scholar
  7. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, Barik S (2007) Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 81:1786–1795PubMedCentralPubMedCrossRefGoogle Scholar
  8. Buchholz UJ, Granzow H, Schuldt K, Whitehead SS, Murphy BR, Collins PL (2000) Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): Effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol 74:1187–1199PubMedCentralPubMedCrossRefGoogle Scholar
  9. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82:12191–12204PubMedCentralPubMedCrossRefGoogle Scholar
  10. Collins PL, Murphy BR (2005) New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2:166–173PubMedCentralPubMedCrossRefGoogle Scholar
  11. Connors M, Collins PL, Firestone CY, Murphy BR (1991) Respiratory syncytial virus (RSV) F, G, M2 (22 K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65:1634–1637PubMedCentralPubMedGoogle Scholar
  12. Crowe JE Jr, Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR (1994) Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691–699PubMedCrossRefGoogle Scholar
  13. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR (1995) Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:847–855PubMedCrossRefGoogle Scholar
  14. Firestone CY, Whitehead SS, Collins PL, Murphy BR, Crowe JE Jr (1996) Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology 225:419–422PubMedCrossRefGoogle Scholar
  15. Friedewald WT, Forsyth BR, Smith CB, Gharpure MA, Chanock RM (1968) Low-temperature-grown RS virus in adult volunteers. JAMA 203:690–694CrossRefGoogle Scholar
  16. Fuentes S, Tran KC, Luthra P, Teng MN, He B (2007) Function of the respiratory syncytial virus small hydrophobic protein. J Virol 81:8361–8366PubMedCentralPubMedCrossRefGoogle Scholar
  17. Gharpure MA, Wright PF, Chanock RM (1969) Temperature-sensitive mutants of respiratory syncytial virus. J Virol 3:414–421PubMedCentralPubMedGoogle Scholar
  18. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G (2009) Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 28:655–658PubMedCrossRefGoogle Scholar
  19. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR (2000) Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18:1763–1772PubMedCrossRefGoogle Scholar
  20. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598PubMedCrossRefGoogle Scholar
  21. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA (2006) Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176:1600–1608PubMedGoogle Scholar
  22. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB (2011) Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204:845–853PubMedCrossRefGoogle Scholar
  23. Jin H, Clarke D, Zhou HZ, Cheng X, Coelingh K, Bryant M, Li S (1998) Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 251:206–214PubMedCrossRefGoogle Scholar
  24. Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL (2012) Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30:959–968PubMedCentralPubMedCrossRefGoogle Scholar
  25. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR (1999) The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 17:1416–1424PubMedCrossRefGoogle Scholar
  26. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS (1997a) Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 94:13961–13966PubMedCentralPubMedCrossRefGoogle Scholar
  27. Karron RA, Wright PF, Crowe JE Jr, Clements ML, Thompson J, Makhene M, Casey R, Murphy BR (1997b) Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J Infect Dis 176:1428–1436PubMedCrossRefGoogle Scholar
  28. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL (2005) Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191:1093–1104PubMedCrossRefGoogle Scholar
  29. Kim HW, Arrobio JO, Pyles G, Brandt CD, Camargo E, Chanock RM, Parrott RH (1971) Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 48:745–755PubMedGoogle Scholar
  30. Kim HW, Arrobio JO, Brandt CD, Wright P, Hodes D, Chanock RM, Parrott RH (1973) Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 52:56–63PubMedGoogle Scholar
  31. Krempl C, Murphy BR, Collins PL (2002) Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol 76:11931–11942PubMedCentralPubMedCrossRefGoogle Scholar
  32. Luongo C, Yang L, Winter CC, Spann KM, Murphy BR, Collins PL, Buchholz UJ (2009) Codon stabilization analysis of the “248” temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 27:5667–5676PubMedCentralPubMedCrossRefGoogle Scholar
  33. Luongo C, Winter CC, Collins PL, Buchholz UJ (2012) Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 86:10792–10804PubMedCentralPubMedCrossRefGoogle Scholar
  34. Luongo C, Winter CC, Collins PL, Buchholz UJ (2013) Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable a physiologic temperature. J Virol 87: 1985–1996 Google Scholar
  35. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA 109:3089–3094PubMedCentralPubMedCrossRefGoogle Scholar
  36. McKay E, Higgins P, Tyrrell D, Pringle C (1988) Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J Med Virol 25:411–421PubMedCrossRefGoogle Scholar
  37. McLellan JS, Yang Y, Graham BS, Kwong PD (2011) Structure of the respiratory syncytial virus fusion glycoprotein in the post-fusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788–7796PubMedCentralPubMedCrossRefGoogle Scholar
  38. Murphy BR, Collins PL (2002) Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 110:21–27PubMedCentralPubMedGoogle Scholar
  39. Murphy BR, Graham BS, Prince GA, Walsh EE, Chanock RM, Karzon DT, Wright PF (1986) Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 23:1009–1014PubMedCentralPubMedGoogle Scholar
  40. Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A (2007) Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine 25:6409–6422PubMedCentralPubMedCrossRefGoogle Scholar
  41. Pringle CR, Filipiuk AH, Robinson BS, Watt PJ, Higgins P, Tyrrell DA (1993) Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11:473–478PubMedCrossRefGoogle Scholar
  42. Schmidt AC, Wenzke DR, McAuliffe JM, St. Clair M, Elkins WR, Murphy BR, Collins PL (2002) Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76:1089–1099Google Scholar
  43. Skiadopoulos MH, Surman SR, Durbin AP, Collins PL, Murphy BR (2000) Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. Virology 272:225–234PubMedCrossRefGoogle Scholar
  44. Skiadopoulos MH, Surman SR, Riggs JM, Elkins WR, St Claire M, Nishio M, Garcin D, Kolakofsky D, Collins PL, Murphy BR (2002a) Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 297:153–160PubMedCrossRefGoogle Scholar
  45. Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR (2002b) Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 297:136–152PubMedCrossRefGoogle Scholar
  46. Slobod KS, Shenep JL, Lujan-Zilbermann J, Allison K, Brown B, Scroggs RA, Portner A, Coleclough C, Hurwitz JL (2004) Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22:3182–3186PubMedCrossRefGoogle Scholar
  47. Surman SR, Collins PL, Murphy BR, Skiadopoulos MH (2007) An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials. J Virol Methods 141:30–33PubMedCrossRefGoogle Scholar
  48. Tang RS, M. E, Stillman E, Nelson C, Yang C, Song E, Liang B, Shambaugh C, Zuo F, Liem A, Balagot C, Wang K, Galinski M, Esser M (2012) Implication of genetic changes observed in Phase I evaluation of MEDI-534, a live attenuated chimeric bovine human parainfluenza type 3 vectored RSV vaccine. Poster #38, RSV 2012, Santa FE, MNGoogle Scholar
  49. Tang RS, Nguyen N, Zhou H, Jin H (2002) Clustered charge-to-alanine mutagenesis of human respiratory syncytial virus L polymerase generates temperature-sensitive viruses. Virology 302:207–216PubMedCrossRefGoogle Scholar
  50. Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, Reisinger K, Chandler P, Hilty M, Walker RE, Gomez MM, Losonsky GA (2008) Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26:6373–6382PubMedCrossRefGoogle Scholar
  51. Teng MN, Whitehead SS, Bermingham A, Clair MS, Elkins WR, Murphy BR, Collins PL (2000) Recombinant respiratory syncytial virus that does not express the NS1 or M2–2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74:9317–9321PubMedCentralPubMedCrossRefGoogle Scholar
  52. Valarcher JF, Furze J, Wyld S, Cook R, Conzelmann KK, Taylor G (2003) Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol 77:8426–8439PubMedCentralPubMedCrossRefGoogle Scholar
  53. Waris ME, Tsou C, Erdman DD, Day DB, Anderson LJ (1997) Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 71:6935–6939PubMedCentralPubMedGoogle Scholar
  54. Watt PJ, Robinson BS, Pringle CR, Tyrrell DA (1990) Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8:231–236PubMedCrossRefGoogle Scholar
  55. Whitehead SS, Firestone CY, Collins PL, Murphy BR (1998a) A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247:232–239CrossRefGoogle Scholar
  56. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR (1998b) Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72:4467–4471Google Scholar
  57. Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, Collins PL, Murphy BR (1999a) Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 73:3438–3442PubMedCentralPubMedGoogle Scholar
  58. Whitehead SS, Firestone CY, Karron RA, Crowe JE Jr, Elkins WR, Collins PL, Murphy BR (1999b) Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 73:871–877PubMedCentralPubMedGoogle Scholar
  59. Whitehead SS, Hill MG, Firestone CY, St Claire M, Elkins WR, Murphy BR, Collins PL (1999c) Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 73:9773–9780PubMedCentralPubMedGoogle Scholar
  60. Wright PF, Mills Jv, Chanock RM (1971) Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J Infect Dis 124:505–511PubMedCrossRefGoogle Scholar
  61. Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT (1976) Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 88:931–936PubMedCrossRefGoogle Scholar
  62. Wright PF, Belshe RB, Kim HW, Van Voris LP, Chanock RM (1982) Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun 37:397–400PubMedCentralPubMedGoogle Scholar
  63. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR (2000) Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182:1331–1342PubMedCrossRefGoogle Scholar
  64. Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O’Shea A, Ikizler MR, Zhu Y, Collins PL, Cutland C, Randolph VB, Deatly AM, Hackell JG, Gruber WC, Murphy BR (2006) The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 193:573–581PubMedCrossRefGoogle Scholar
  65. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O’Shea AF, Gruber WC, Murphy BR (2007) The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25:7372–7378PubMedCentralPubMedCrossRefGoogle Scholar
  66. Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA (2010) Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 84:1148–1157PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Ruth A. Karron
    • 1
  • Ursula J. Buchholz
    • 2
  • Peter L. Collins
    • 2
  1. 1.Center for Immunization Research, Department of International Health, Bloomberg School of Public HealthJohns Hopkins UniversityBaltimoreUSA
  2. 2.Laboratory of Infectious Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations